Kathleen J Ramos1, Jenna Sykes2, Sanja Stanojevic3, Xiayi Ma2, Joshua S Ostrenga4, Aliza Fink4, Bradley S Quon5, Bruce C Marshall4, Albert Faro4, Kristofer Petren4, Alexander Elbert4, Christopher H Goss6, Anne L Stephenson7. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA. Electronic address: ramoskj@uw.edu. 2. Division of Respirology, St. Michael's Hospital, Toronto, ON, Canada. 3. Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada. 4. Cystic Fibrosis Foundation, Bethesda, MD. 5. Division of Respirology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 6. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA; Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, WA. 7. Division of Respirology, St. Michael's Hospital, Toronto, ON, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND: Understanding how health outcomes differ for patients with advanced cystic fibrosis (CF) lung disease living in the United States compared with Canada has health policy implications. RESEARCH QUESTION: What are rates of lung transplant (LTx) and rates of death without LTx in the United States and Canada among individuals with FEV1 < 40% predicted? STUDY DESIGN AND METHODS: This was a retrospective population-based cohort study, 2005 to 2016, using the US CF Foundation, United Network for Organ Sharing, and Canadian CF registries. Individuals with CF and at least two FEV1 measurements < 40% predicted within a 5-year period, age ≥ 6 years, without prior LTx were included. Multivariable competing risk regression for time to death without LTx (LTx as a competing risk) and time to LTx (death as a competing risk) was performed. RESULTS: There were 5,899 patients (53% male) and 905 patients (54% male) with CF with FEV1 < 40% predicted living in the United States and Canada, respectively. Multivariable competing risk regression models identified an increased risk of death without LTx (hazard ratio [HR], 1.79; 95% CI, 1.52-2.1) and decreased LTx (HR, 0.66; 95% CI, 0.58-0.74) among individuals in the United States compared with Canada. More pronounced differences were seen in the patients in the United States with Medicaid/Medicare insurance compared with Canadians (multivariable HR for death without LTx, 2.24 [95% CI, 1.89-2.64]; multivariable HR for LTx, 0.54 [95% CI, 0.47-0.61]). Patients of nonwhite race were also disadvantaged (multivariable HR for death without LTx, 1.56 [95% CI, 1.32-1.84]; multivariable HR for LTx, 0.47 [95% CI, 0.36-0.62]). INTERPRETATION: There are lower rates of LTx and an increased risk of death without LTx for US patients with CF with FEV1 < 40% predicted compared with Canadian patients. Findings are more striking among US patients with CF with Medicaid/Medicare health insurance, and nonwhite patients in both countries, raising concerns about underuse of LTx among vulnerable populations.
BACKGROUND: Understanding how health outcomes differ for patients with advanced cystic fibrosis (CF) lung disease living in the United States compared with Canada has health policy implications. RESEARCH QUESTION: What are rates of lung transplant (LTx) and rates of death without LTx in the United States and Canada among individuals with FEV1 < 40% predicted? STUDY DESIGN AND METHODS: This was a retrospective population-based cohort study, 2005 to 2016, using the US CF Foundation, United Network for Organ Sharing, and Canadian CF registries. Individuals with CF and at least two FEV1 measurements < 40% predicted within a 5-year period, age ≥ 6 years, without prior LTx were included. Multivariable competing risk regression for time to death without LTx (LTx as a competing risk) and time to LTx (death as a competing risk) was performed. RESULTS: There were 5,899 patients (53% male) and 905 patients (54% male) with CF with FEV1 < 40% predicted living in the United States and Canada, respectively. Multivariable competing risk regression models identified an increased risk of death without LTx (hazard ratio [HR], 1.79; 95% CI, 1.52-2.1) and decreased LTx (HR, 0.66; 95% CI, 0.58-0.74) among individuals in the United States compared with Canada. More pronounced differences were seen in the patients in the United States with Medicaid/Medicare insurance compared with Canadians (multivariable HR for death without LTx, 2.24 [95% CI, 1.89-2.64]; multivariable HR for LTx, 0.54 [95% CI, 0.47-0.61]). Patients of nonwhite race were also disadvantaged (multivariable HR for death without LTx, 1.56 [95% CI, 1.32-1.84]; multivariable HR for LTx, 0.47 [95% CI, 0.36-0.62]). INTERPRETATION: There are lower rates of LTx and an increased risk of death without LTx for US patients with CF with FEV1 < 40% predicted compared with Canadian patients. Findings are more striking among US patients with CF with Medicaid/Medicare health insurance, and nonwhite patients in both countries, raising concerns about underuse of LTx among vulnerable populations.
Authors: C A Merlo; S C Clark; G J Arnaoutakis; N Yonan; D Thomas; A Simon; R Thompson; H Thomas; J Orens; A S Shah Journal: Am J Transplant Date: 2015-03-24 Impact factor: 8.086
Authors: Daniel C Chambers; Wida S Cherikh; Michael O Harhay; Don Hayes; Eileen Hsich; Kiran K Khush; Bruno Meiser; Luciano Potena; Joseph W Rossano; Alice E Toll; Tajinder P Singh; Aparna Sadavarte; Andreas Zuckermann; Josef Stehlik Journal: J Heart Lung Transplant Date: 2019-08-08 Impact factor: 10.247
Authors: Siddhartha G Kapnadak; Emily Dimango; Denis Hadjiliadis; Sarah E Hempstead; Erin Tallarico; Joseph M Pilewski; Albert Faro; James Albright; Christian Benden; Shaina Blair; Elisabeth P Dellon; Daniel Gochenour; Peter Michelson; Baharak Moshiree; Isabel Neuringer; Carl Riedy; Teresa Schindler; Lianne G Singer; Dave Young; Lauren Vignola; Joan Zukosky; Richard H Simon Journal: J Cyst Fibros Date: 2020-02-27 Impact factor: 5.482
Authors: Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy Journal: Lancet Date: 2019-10-31 Impact factor: 79.321
Authors: Emily A Knapp; Aliza K Fink; Christopher H Goss; Ase Sewall; Josh Ostrenga; Christopher Dowd; Alexander Elbert; Kristofer M Petren; Bruce C Marshall Journal: Ann Am Thorac Soc Date: 2016-07
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700
Authors: Patricia J Rodriguez; David L Veenstra; Patrick J Heagerty; Christopher H Goss; Kathleen J Ramos; Aasthaa Bansal Journal: Value Health Date: 2021-12-22 Impact factor: 5.101
Authors: Ann L Jennerich; Joseph B Pryor; Travis Y Hee Wai; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos Journal: J Cyst Fibros Date: 2021-12-23 Impact factor: 5.527